Breaking Down Revenue Trends: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.

PTC's revenue soars, Taro faces challenges.

__timestampPTC Therapeutics, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201422963000759285000
Thursday, January 1, 201536766000862944000
Friday, January 1, 201682705000950751000
Sunday, January 1, 2017194392000879387000
Monday, January 1, 2018264734000661913000
Tuesday, January 1, 2019306980000669893000
Wednesday, January 1, 2020380766000644769000
Friday, January 1, 2021538593000548970000
Saturday, January 1, 2022698801000561347000
Sunday, January 1, 2023937822000572952000
Monday, January 1, 2024629182000
Loading chart...

Unleashing the power of data

Revenue Trends: PTC Therapeutics vs. Taro Pharmaceuticals

In the dynamic world of pharmaceuticals, revenue trends offer a glimpse into a company's growth and market position. Over the past decade, PTC Therapeutics, Inc. has shown a remarkable upward trajectory, with revenue increasing from a modest $23 million in 2014 to an impressive $938 million by 2023. This represents a staggering growth of over 4000%, highlighting PTC's strategic advancements and market penetration.

Conversely, Taro Pharmaceutical Industries Ltd. has experienced a more fluctuating revenue pattern. Starting at $759 million in 2014, Taro's revenue peaked at $951 million in 2016, before settling at $573 million in 2023. This 24% decline from its peak suggests challenges in maintaining its market share.

These contrasting trends underscore the competitive landscape of the pharmaceutical industry, where innovation and adaptability are key to sustained success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025